Search - tctmd.com

Displaying 461 - 480 of 629

Sort: Relevancy | Date

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

The Biggest News of 2019: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2019: TCTMD’s Top 10

January 01, 2020

Year in Review: Physicians Pick the Biggest News of 2019

News Features

Year in Review: Physicians Pick the Biggest News of 2019

TCTMD News Team

December 30, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Diastolic Dysfunction Does Not Negate Health Status Benefits of TAVR

News Daily News

Diastolic Dysfunction Does Not Negate Health Status Benefits of TAVR

November 27, 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

Women More Likely Than Men to Develop Heart Failure After STEMI

News Daily News

Women More Likely Than Men to Develop Heart Failure After STEMI

November 04, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

Inequities Exist in ED Triage of Heart Failure Patients—With Repercussions

News Daily News

Inequities Exist in ED Triage of Heart Failure Patients—With Repercussions

October 30, 2019

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

News Daily News

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Michael O'Riordan

October 29, 2019

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

September 24, 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

September 23, 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

September 13, 2019

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

September 13, 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.